Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncol Lett
Päätekijät: Kim, Ju-Hwi, Jung, Tae-Young, Hwang, Eu Chang, Jung, Sung-Hoon, Jung, Shin, Kim, In-Young, Jang, Woo-Youl, Moon, Kyung-Sub, Lee, Kyung-Hwa, Kim, Seul-Kee
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: D.A. Spandidos 2017
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://ncbi.nlm.nih.gov/pubmed/28927109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia